An FDA advisory panel voted narrowly in favor of expanding compounding for certain unapproved peptides, setting up a consequential next step in a high-profile regulatory fight. The panel supported allowing compounding pharmacies to manufacture epitalon while voting against manufacturing emideltide, in deliberations that followed similar recommendations for additional peptides earlier. The vote is non-binding, but it signals how far the Pharmacy Compounding Advisory Committee’s recommendations could push the FDA toward lifting or relaxing current restrictions. The discussion also reflects broader scrutiny of whether limited evidence for safety and effectiveness should be expanded through compounding channels. For the biotech and pharma sector, the outcome could reshape incentives and risk tolerance around products that have not cleared standard FDA approval pathways.